NGS Streamlines Biomarker Testing in Solid Tumors
According to Chen, PharmD, MS, BCOP, CPP, next-generation sequencing (NGS) improves biomarker testing and treatment planning in solid tumors.
- Experts such as Traina, MD, FASCO, and Demetria Smith-Graziani, MD, MPH, discuss the benefits of NGS.
- Other notable experts include Mark Agulnik, MD, Mrinal M. Zuckerman, MD, and Daniel Lefler, MD.
NGS streamlines biomarker testing, leading to more effective treatment planning.
Additional experts, including Naval G. Daver, MD, Jessica Altman, MD, and Amir T. Roboz, MD, contribute to the discussion.
Author's summary: NGS improves biomarker testing in solid tumors.